InnoCare Pharma Limited reported that all 24 proposals tabled at its Annual General Meeting (AGM) on 16 June 2026 received the requisite shareholder support, with each ordinary resolution gaining well above the simple-majority threshold and the special resolution surpassing the 75% requirement.

The company’s 2025 financial statements, annual report and board work report were endorsed with approval rates of 99.85 %, 99.85 % and 99.84 %, respectively. The 2025 profit‐distribution plan attracted 99.89 % support.

Authorisations for capital management also passed comfortably: • A 20 % general issuance mandate received 88.01 % approval. • A 10 % share-repurchase mandate passed with 99.83 % support. • Extension of the issuance mandate by the amount of repurchased shares secured 87.61 % approval.

Shareholders re-elected three directors—Dr Yigong Shi, Mr Ronggang Xie and Dr Dandan Dong—with backing ranging from 97.77 % to 99.18 %. Ernst & Young and Ernst & Young Hua Ming LLP were re-appointed as auditors with 99.41 % support.

Incentive-related items also cleared: • Grants of 10.78 million and 2.15 million restricted share units (RSUs) to Dr Jisong Cui and Dr Renbin Zhao achieved 92.88 % and 92.89 % approval, respectively, after required abstentions by related parties. • The 2026 RMB Share Incentive Scheme, its assessment measures, mandate limit and related board authorisations were each approved with about 94.6 %–94.7 % of votes in favour.

Governance enhancements moved forward as shareholders endorsed amendments to the company’s meeting rules (83.35 %–83.35 % approval) and adopted the sixth amended and restated memorandum and articles of association via a special resolution supported by 99.47 % of votes cast.

Voting base and participation: • Total issued shares: 1.76 billion. • Voting-eligible shares: 1.69 billion after excluding 2.49 million treasury shares and 70.31 million shares held under share award schemes. • Specific resolutions required additional abstentions from insiders, reducing eligible votes to 1.22 billion for RSU grants and 1.42 billion for the 2026 incentive scheme.

All directors attended the AGM in person or electronically, and Computershare Hong Kong Investor Services acted as scrutineer.